XML 28 R17.htm IDEA: XBRL DOCUMENT v3.25.1
Segment
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Segment
The chief operating decision maker for the Company is the Chief Executive Officer, who reviews financial information presented on a consolidated basis for purposes of allocating resources and assessing financial performance. The Company has a single reporting unit associated with the development and commercialization of diagnostic products and biopharmaceutical services. The accounting policies of the Company's single segment are the same as those described in the summary of significant accounting policies in Note 1, Organization, Description of Business and Summary of Significant Accounting Policies. The chief operating decision maker assesses performance of the Company's single segment and decides how to allocate resources based on consolidated net income. Under the current organizational structure, this measure is not discreetly available or required individually for any of the Company’s business activities and is only available at the consolidated level. The monitoring of budgeted versus actual results are used in assessing performance of the Company's single segment, allocating resources and in establishing management’s compensation. The Company's chief operating decision maker intends for all revenue generating activities to rely on cross-functional activities across the consolidated entity in order to operate. No individual besides the chief operating decision maker has been tasked with reviewing discreet operating results of the business activities, nor is there any intent to bifurcate the overall business review process to produce discreet operating results specific to any of the Company's business activities. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. Consolidated revenue does not include any inter-segment sales or transfers.
Information about reported segment revenue, measures of segment profit or loss, significant segment expenses and reconciliation to income from operations was as follows (in thousands):



Three Months Ended March 31,
March 31, 2025March 31, 2024
Revenue:
Testing revenue$107,309 $90,303 
Product revenue3,580 3,537 
Biopharmaceutical and other revenue3,584 3,004 
Total revenue114,473 96,844 
Cost of revenue:
Cost of testing revenue:
Laboratory supplies and reagents expense13,067 11,918 
Sample collection expense2,825 3,057 
Compensation expense5,611 5,215 
Other cost of testing revenue (1)3,385 2,846 
Allocation of facilities and IT expenses3,372 2,943 
Total cost of testing revenue28,260 25,979 
Cost of product revenue:
Product costs109 1,263 
License fees and royalties324 436 
Other cost of product revenue (2)792 824 
Allocation of facilities and IT expenses197 121 
Total cost of product revenue1,422 2,644 
Cost of biopharmaceutical and other revenue:
Compensation expense1,240 1,462 
Other cost of biopharmaceutical and other revenue (3)1,044 949 
Allocation of facilities and IT expenses414 427 
Total cost of biopharmaceutical and other revenue2,698 2,838 
Intangible asset amortization - cost of revenue2,585 2,915 
Gross profit79,508 62,468 
Operating expenses:
Research and development:
Compensation expense9,748 9,085 
Direct research and development expense4,141 3,874 
Other research and development expenses (4)1,815 1,519 
Allocation of facilities and IT expenses2,016 1,487 
Total research and development17,720 15,965 
Selling and marketing:
Compensation expense17,635 17,622 
Direct marketing expense710 1,138 
Other selling and marketing expenses (5)3,853 3,414 
Allocation of facilities and IT expenses2,256 1,608 
Total selling and marketing24,454 23,782 
General and administrative:
Compensation expense20,173 17,759 
Other general and administrative expenses (6)21,890 15,037 
Allocation of facilities and IT expenses(8,255)(6,586)
Total general and administrative33,808 26,210 
Intangible asset amortization - operating expenses622 738 
Other income, net(4,524)(2,748)
Income tax provision (benefit)381 (44)
Net income (loss)$7,047 $(1,864)
________________
(1)Other cost of testing revenue includes cytopathology services, depreciation and amortization and other expenses.
(2)Other cost of product revenue includes license fees and royalties, depreciation and amortization and other expenses.
(3)Other cost of biopharmaceutical and other revenue includes license fees and royalties, depreciation and amortization and other expenses.
(4)Other research and development expenses includes depreciation and amortization and other expenses.
(5)Other selling and marketing expenses includes travel, entertainment, conference and other expenses.
(6)Other general and administrative expenses includes professional fees, information technology expense, occupancy costs, depreciation and amortization, contingent consideration and other expenses.